Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Update

Check-Cap Ltd. (NASDAQ:CHEK) was the recipient of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 116,000 shares, a decline of 27.5% from the January 31st total of 159,900 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.7% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Check-Cap in a research report on Saturday. They set a “sell” rating for the company.

Check-Cap Stock Up 0.6 %

Shares of NASDAQ CHEK traded up $0.01 during mid-day trading on Wednesday, hitting $0.80. 4,765 shares of the company traded hands, compared to its average volume of 988,913. The business has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.22. The stock has a market capitalization of $4.65 million, a price-to-earnings ratio of -0.27 and a beta of 0.16. Check-Cap has a 1 year low of $0.56 and a 1 year high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.